Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

6(75.0%)

Phase 1

1(12.5%)

Phase 3

1(12.5%)

8Total

Phase 2(6)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06757010Phase 2Active Not Recruiting

A Study of NE3107 in Early Parkinson's

Role: lead

NCT06847191Phase 2Recruiting

NE3107 in Adults With Neurological Symptoms of Long COVID

Role: lead

NCT05970575Phase 2Terminated

Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury

Role: collaborator

NCT05227820Phase 2Completed

Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia

Role: collaborator

NCT04112199Phase 2Terminated

A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites

Role: lead

NCT04669028Phase 3Completed

A Phase 3 Study of NE3107 in Probable Alzheimer's Disease

Role: lead

NCT05083260Phase 1Completed

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

Role: lead

NCT03107091Phase 2Completed

Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites

Role: lead

All 8 trials loaded